Individuallyizing the treatment of advanced NSCLC

Chaired by Carlos Gil Ferreira

14:00–15:00, Panama Salon 1, Level 4, El Riu Plaza Hotel
Saturday 27th August 2016
Learning Objectives

After attending the symposium, learners will be able to:

– Assess the new treatment and diagnosis paradigms for non-mutated advanced and metastatic non-squamous NSCLC, and explain how to best apply them to individualized patient care in a Latin–American context

– Describe the rapidly expanding and complex range of treatment and diagnosis options for advanced and metastatic squamous NSCLC, and explain how to best apply them to individualized patient care in a Latin–American context

Program

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:05</td>
<td>Welcome and introduction</td>
<td>Chair: Carlos Gil Ferreira (Brazil)</td>
</tr>
<tr>
<td>14:05 – 14:30</td>
<td>Management of non-squamous NSCLC patients without \textit{EGFR/ALK} mutations</td>
<td>Mauricio Cuello (Uruguay)</td>
</tr>
<tr>
<td>14:30 – 14:55</td>
<td>Navigating the advanced squamous NSCLC patient pathway</td>
<td>Johan Vansteenkiste (Belgium)</td>
</tr>
<tr>
<td>14:55 – 15:00</td>
<td>Closing remarks</td>
<td>Chair: Carlos Gil Ferreira (Brazil)</td>
</tr>
</tbody>
</table>
Dear Colleagues,

Welcome to Panama and thank you for attending this satellite symposium entitled ‘Individualizing the treatment of advanced NSCLC’ at the IASLC 7th Latin American Conference on Lung Cancer (LALCA 2016).

Panama City provides a cosmopolitan and culturally vibrant host backdrop for this conference that brings together a unique community of medical professionals from across the Latin-America region. The aim of this symposium is to facilitate the management of squamous and non-squamous NSCLC, and the implementation of new discoveries in clinical practice. It will also address the challenges facing clinicians in the Latin-America region in an increasingly complex treatment landscape.

During this session, the expert Faculty will guide us through this complexity by placing the latest developments in advanced NSCLC into the context of treatment. They will provide their insights into how we can use our biological knowledge not only to improve treatment pathways, but also on how to maximize treatment outcomes by understanding different approaches.

We hope that you find this symposium educational and that it will further your understanding of this evolving field. Accordingly, we aim to provide maximum interaction and discourse between Faculty and audience so that we may work together to optimize patient outcomes.

We would be grateful if you would kindly provide your feedback by completing the evaluation form provided with this booklet.

Yours faithfully,

Carlos Gil Ferreira – Chair
Carlos Gil Ferreira
(Symposium Chair)
D’Or Institute of Research and Education, Rio de Janeiro, Brazil

Carlos Gil Ferreira MD, PhD was trained as a medical oncologist at the Brazilian National Cancer Institute (INCA) back in 1997. He pursued a PhD program in molecular oncology and a Fellowship in thoracic oncology at the Free University in Amsterdam until 2001. Back in Brazil he was the Director of Clinical Research at INCA between 2001 and 2011, where he established the National Tumor and DNA Bank. Within the Ministry of Health he served as the founder and Chair of both the Brazilian Clinical Cancer Research Network (RNPCC) and the Brazilian Drug Discovery Network (REDEFAC) between 2012 and 2015.

Dr Ferreira is currently the CMO and Head of the Thoracic Division (Neotorax Program) of D’Or Oncology and Head of the Oncology Branch at D’Or Institute for Research and Education in Rio de Janeiro. Dr Ferreira is deeply involved in initiatives to increase access to molecular testing and cancer drugs for lung cancer patients in Brazil and Latin America, leading discussions within different stakeholders at a global level: government, diagnostic and pharmaceutical companies, regulatory agencies, payers, academia and venture capital players. Dr Ferreira is the co-chair of the IASLC Fellowship and Career Development Committee and member of the AACR International Affairs Committee. He has published over 120 papers and book chapters in peer-reviewed journals.
Mauricio Cuello  
Hospital de Clínicas Montevideo, Uruguay

Dr Mauricio Cuello became a Doctor in Medicine at the Universidad de la Republica, UdelaR, Montevideo-Uruguay in 2000. In 2004, he specialized in Medical Oncology at Hospital de Clinicas UdelaR.

He embarked on a Fellowship in Thoracic Oncology at the Hospital Germans trias i Pujol, Badalona, Barcelona, Spain from 2004–2009.

Now Dr Cuello is an Associate Professor at the Department of Oncology, Hospital de Clínicas, Montevideo, Uruguay and has been there since 2011.

His research activities include being the Coordinator of the Uruguayan Cooperative Oncology Group GOCUR and Director of the Oncology Respiratory Disease Unit at the Department of Oncology, Hospital de Clinicas, UdelaR from 2011 onwards. He has also been the Deputy Director at the National Cancer Institute since 2015.

In his professional career, Dr Cuello has been the Clinical Coordinator in the Department of Oncology, Institute Dexeus, Barcelona, Spain from 2007–2011 and the Trial Clinical Manager at Boehringer Ingelheim, Barcelona, Spain from 2009–2011.
Johan Vansteenkiste
University Hospital Leuven, Belgium

Johan Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital.

Professor Vansteenkiste studied Medicine at the University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the University of Leuven in 1996.

Professor Vansteenkiste is an active member of different international societies such as ESMO, IASLC, ASCO, ERS and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and member of the ERS School Board in 2009-2012. He was member of the Board of Directors of IASLC in 2009-2013. He is member of the ESMO Lung Educational Group and Guidelines Group, and chaired the European Lung Cancer Conference in April 2015.

He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor of the Annals of Oncology, member of the editorial board of several other journals, and author or co-author of more than 250 peer-reviewed papers and book chapters.
Symposium information

Organizers
This educational activity has been planned and independently implemented by Springer Healthcare IME. Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Science+Business Media global publishing group.

Filming and photography
Springer Healthcare IME may film or take photographs at the symposium that may be used in publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team your objection to this, your consent will be implied.

Educational sponsorship
This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.
Notes